HGS cheered by mid-stage lupus data

Human Genome Sciences is touting mid-stage data that shows its lupus treatment significantly reducing disease activity. LymphoStat-B reduced disease activity after 52 weeks of therapy and more than 95 percent of the patients in the trial signed on for a new study of the therapy. Investigators will now focus on patients response rates as a primary endpoint in Phase III.

- check out this release on the data
- read the AP report

Related Articles:
HGS marks success of Albuferon in IIb. Report
Novartis inks major licensing pact with HGS. Report
HGS adds positive data in extended lupus trial. Report
HGS signs $425M deal for BioMed Realty campus. Report
Feds ink HGS contract. Report